In ₹ Crore except Per Share Latest Annual | BPLPHARMA FY23 | JENBURPH FY26 | KPL FY24 | MAKERSL FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 37.02× | — | — | — | — | |
| Growth | ||||||
| Revenue CAGR 3Y | — | ◆ 7.26% | — | 5.77% | 6.51% | |
| Revenue CAGR 5Y | — | ◆ 9.07% | — | 1.55% | 5.31% | |
| Net Income CAGR 3Y | — | 12.18% | — | — | 12.18% | |
| Profitability | ||||||
| EBITDA Margin | 9.80% | ◆ 23.81% | 21.69% | 1.45% | 21.69% -55% | |
| Net Income Margin | 11.16% | ◆ 20.59% | — | -3.42% | 8.59% +30% | |
| Return on Common Equity | ◆ 12.74% | — | — | -3.16% | -3.16% +503% | |
| Return on Capital Employed | — | — | 19.18% | — | 19.18% | |
| Return on Assets | 7.90% | ◆ 15.37% | — | -2.34% | 6.51% +21% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.04× | — | 0.43× | 0.05× | 0.24× -83% | |
| Interest Coverage | ◆ 7.10× | — | 4.54× | -3.91× | 0.31× +2154% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹218 Cr | ₹169 Cr | ₹307 Cr | ₹50.3 Cr | ₹169 Cr +29% | |
| Net Income | ₹24.3 Cr | ₹34.7 Cr | — | −₹1.7 Cr | ₹16.5 Cr +47% | |
| Total Assets | ₹308 Cr | ₹226 Cr | ₹398 Cr | ₹73.5 Cr | ₹226 Cr +36% | |
| EPS | ₹42.14 | — | — | ₹-2.91 | ₹-2.91 +1548% | |